Growth & profitability
- Revenue has declined 2.9% per year over the past 5 years.
- Operating margin has expanded, at -9.8% in the latest year.
- Free cash flow has declined 17.5% per year over the past 5 years.
ANIK Financials Anika Therapeutics, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $113M | -$11M | 56.6% | -9.8% | $4M | — | $57M |
| 2024 | $120M | -$56M | 63.4% | -4.3% | -$2M | — | $56M |
| 2023 | $121M | -$83M | 68.3% | 0.7% | -$7M | — | $69M |
| 2022 | $114M | -$15M | 64.3% | 3.2% | -$3M | — | $86M |
| 2021 | $148M | $4M | 56.1% | 1.8% | $3M | — | $94M |
| 2020 | $130M | -$24M | 52.9% | -21.7% | $11M | — | $96M |
| 2019 | $115M | $27M | 74.9% | 29.9% | $34M | $0 | $157M |
| 2018 | $106M | $19M | 70.4% | 20.6% | $30M | — | $89M |
| 2017 | $113M | $32M | 75.9% | 40.3% | $32M | — | $133M |
| 2016 | $103M | $33M | 76.8% | 49.0% | $10M | — | $104M |
| 2015 | — | $31M | — | — | $31M | — | $111M |
| 2014 | — | $38M | — | — | $38M | — | $100M |
| 2013 | — | $21M | — | — | $25M | — | $63M |
| 2012 | — | $12M | — | — | $9M | $10M | $44M |
| 2011 | — | $8M | — | — | $9M | $13M | $36M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $30M | -$5M | 64.2% | -18.5% | -$6M | — | $41M |
| Dec '25 | $31M | $292000 | 62.6% | 2.1% | $4M | — | $57M |
| Sep '25 | $28M | -$2M | 56.0% | -11.6% | $5M | — | $58M |
| Jun '25 | $28M | -$4M | 50.9% | -14.8% | -$2M | — | $53M |
| Mar '25 | $26M | -$5M | 56.1% | -16.4% | -$3M | — | $53M |
| Dec '24 | $31M | -$22M | 56.0% | -2.3% | $275000 | — | $56M |
| Sep '24 | $30M | -$30M | 65.7% | -0.3% | $4M | — | $62M |
| Jun '24 | $31M | -$88000 | 66.7% | -5.9% | -$4M | — | $63M |
| Mar '24 | $29M | -$5M | 65.4% | -8.6% | -$2M | — | $69M |
| Dec '23 | -$3M | -$63M | -199.1% | -852.1% | $2M | — | $69M |
| Sep '23 | $41M | -$7M | 60.2% | -18.5% | $6M | — | $71M |
| Jun '23 | $44M | -$3M | 65.4% | -8.2% | -$10M | — | $65M |
| Mar '23 | $38M | -$10M | 60.2% | -33.1% | -$5M | — | $80M |
| Dec '22 | $40M | -$5M | 60.9% | -16.8% | -$2M | — | $86M |
| Sep '22 | $40M | -$4M | 56.6% | -14.4% | $1M | — | $88M |
| Jun '22 | $40M | -$3M | 62.7% | -8.5% | $1M | — | $91M |
| Mar '22 | $37M | -$3M | 59.4% | -9.7% | -$3M | — | $90M |
| Dec '21 | $36M | -$6M | 50.6% | -25.5% | $3M | — | $94M |
| Sep '21 | $40M | $558000 | 58.2% | 3.3% | $778000 | — | $91M |
| Jun '21 | $38M | $7M | 54.6% | 24.1% | $2M | — | $97M |
Valuation over time
How the market has priced ANIK against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 3.4× (Mar '23) to 1.7× (Jun '26).
P/S
Frequently asked questions
Is ANIK growing its revenue and profit?
Over the past 5 years, Anika Therapeutics, Inc.'s revenue has declined 2.9% per year. These are computed facts, not advice.
How much debt does ANIK have?
As of FY2025, Anika Therapeutics, Inc. reported — of total debt against $57M of cash.
What is ANIK's profit margin?
In FY2025, gross margin was 56.6%, operating margin -9.8%, and net margin -9.8%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.